Cetuximab  ||| S:0 E:10 ||| NNP
for  ||| S:10 E:14 ||| IN
the  ||| S:14 E:18 ||| DT
treatment  ||| S:18 E:28 ||| NN
of  ||| S:28 E:31 ||| IN
recurrent  ||| S:31 E:41 ||| NN
and ||| S:41 E:44 ||| CC
/ ||| S:44 E:45 ||| NNP
or  ||| S:45 E:48 ||| CC
metastatic  ||| S:48 E:59 ||| JJ
squamous  ||| S:59 E:68 ||| JJ
cell  ||| S:68 E:73 ||| NN
carcinoma  ||| S:73 E:83 ||| NN
of  ||| S:83 E:86 ||| IN
the  ||| S:86 E:90 ||| DT
head  ||| S:90 E:95 ||| NN
and  ||| S:95 E:99 ||| CC
neck  ||| S:99 E:104 ||| NN
This  ||| S:104 E:109 ||| DT
paper  ||| S:109 E:115 ||| NN
presents  ||| S:115 E:124 ||| VBZ
a  ||| S:124 E:126 ||| DT
summary  ||| S:126 E:134 ||| NN
of  ||| S:134 E:137 ||| IN
the  ||| S:137 E:141 ||| DT
evidence  ||| S:141 E:150 ||| NN
review  ||| S:150 E:157 ||| NN
group  ||| S:157 E:163 ||| NN
( ||| S:163 E:164 ||| -LRB-
ERG ||| S:164 E:167 ||| NNP
)  ||| S:167 E:169 ||| -RRB-
report  ||| S:169 E:176 ||| NN
into  ||| S:176 E:181 ||| IN
the  ||| S:181 E:185 ||| DT
clinical  ||| S:185 E:194 ||| JJ
effectiveness  ||| S:194 E:208 ||| NN
and  ||| S:208 E:212 ||| CC
cost-effectiveness  ||| S:212 E:231 ||| JJ
of  ||| S:231 E:234 ||| IN
cetuximab  ||| S:234 E:244 ||| NN
for  ||| S:244 E:248 ||| IN
recurrent  ||| S:248 E:258 ||| NN
and ||| S:258 E:261 ||| CC
/ ||| S:261 E:262 ||| NNP
or  ||| S:262 E:265 ||| CC
metastatic  ||| S:265 E:276 ||| JJ
squamous  ||| S:276 E:285 ||| JJ
cell  ||| S:285 E:290 ||| NN
carcinoma  ||| S:290 E:300 ||| NN
of  ||| S:300 E:303 ||| IN
the  ||| S:303 E:307 ||| DT
head  ||| S:307 E:312 ||| NN
and  ||| S:312 E:316 ||| CC
neck  ||| S:316 E:321 ||| NN
( ||| S:321 E:322 ||| -LRB-
SCCHN ||| S:322 E:327 ||| NNP
)  ||| S:327 E:329 ||| -RRB-
based  ||| S:329 E:335 ||| VBN
upon  ||| S:335 E:340 ||| IN
a  ||| S:340 E:342 ||| DT
review  ||| S:342 E:349 ||| NN
of  ||| S:349 E:352 ||| IN
the  ||| S:352 E:356 ||| DT
manufacturer ||| S:356 E:368 ||| NN
's  ||| S:368 E:371 ||| POS
submission  ||| S:371 E:382 ||| NN
to  ||| S:382 E:385 ||| TO
the  ||| S:385 E:389 ||| DT
National  ||| S:389 E:398 ||| NNP
Institute  ||| S:398 E:408 ||| NNP
for  ||| S:408 E:412 ||| IN
Health  ||| S:412 E:419 ||| NNP
and  ||| S:419 E:423 ||| CC
Clinical  ||| S:423 E:432 ||| NNP
Excellence  ||| S:432 E:443 ||| NNP
( ||| S:443 E:444 ||| -LRB-
NICE ||| S:444 E:448 ||| NNP
)  ||| S:448 E:450 ||| -RRB-
as  ||| S:450 E:453 ||| IN
part  ||| S:453 E:458 ||| NN
of  ||| S:458 E:461 ||| IN
the  ||| S:461 E:465 ||| DT
single  ||| S:465 E:472 ||| JJ
technology  ||| S:472 E:483 ||| NN
appraisal  ||| S:483 E:493 ||| NN
( ||| S:493 E:494 ||| -LRB-
STA ||| S:494 E:497 ||| NNP
)  ||| S:497 E:499 ||| -RRB-
process ||| S:499 E:506 ||| NN
.  ||| S:506 E:508 ||| .
The  ||| S:508 E:512 ||| DT
submission ||| S:512 E:522 ||| NN
's  ||| S:522 E:525 ||| POS
evidence  ||| S:525 E:534 ||| NN
came  ||| S:534 E:539 ||| VBD
from  ||| S:539 E:544 ||| IN
a  ||| S:544 E:546 ||| DT
single  ||| S:546 E:553 ||| JJ
reasonably  ||| S:553 E:564 ||| RB
high-quality  ||| S:564 E:577 ||| JJ
randomised  ||| S:577 E:588 ||| NNS
controlled  ||| S:588 E:599 ||| VBN
trial  ||| S:599 E:605 ||| NN
( ||| S:605 E:606 ||| -LRB-
RCT ||| S:606 E:609 ||| NNP
)  ||| S:609 E:611 ||| -RRB-
[ ||| S:611 E:612 ||| -LRB-
EXTREME  ||| S:612 E:620 ||| NNP
( ||| S:620 E:621 ||| -LRB-
Erbitux  ||| S:621 E:629 ||| NNP
in  ||| S:629 E:632 ||| IN
First-Line  ||| S:632 E:643 ||| NNP
Treatment  ||| S:643 E:653 ||| NNP
of  ||| S:653 E:656 ||| IN
Recurrent  ||| S:656 E:666 ||| NNP
or  ||| S:666 E:669 ||| CC
Metastatic  ||| S:669 E:680 ||| NNP
Head  ||| S:680 E:685 ||| NNP
and  ||| S:685 E:689 ||| CC
Neck  ||| S:689 E:694 ||| NNP
Cancer ||| S:694 E:700 ||| NNP
) ||| S:700 E:701 ||| -RRB-
;  ||| S:701 E:703 ||| :
n  ||| S:703 E:705 ||| CD
=  ||| S:705 E:707 ||| SYM
442 ||| S:707 E:710 ||| CD
]  ||| S:710 E:712 ||| -RRB-
comparing  ||| S:712 E:722 ||| FW
cetuximab  ||| S:722 E:732 ||| FW
plus  ||| S:732 E:737 ||| FW
chemotherapy  ||| S:737 E:750 ||| FW
( ||| S:750 E:751 ||| -LRB-
CTX ||| S:751 E:754 ||| NNP
)  ||| S:754 E:756 ||| -RRB-
with  ||| S:756 E:761 ||| IN
CTX  ||| S:761 E:765 ||| NNP
alone ||| S:765 E:770 ||| RB
.  ||| S:770 E:772 ||| .
Cetuximab  ||| S:772 E:782 ||| NNP
plus  ||| S:782 E:787 ||| CC
CTX  ||| S:787 E:791 ||| NNP
had  ||| S:791 E:795 ||| VBD
significant  ||| S:795 E:807 ||| JJ
effects  ||| S:807 E:815 ||| NNS
compared  ||| S:815 E:824 ||| VBN
with  ||| S:824 E:829 ||| IN
CTX  ||| S:829 E:833 ||| NNP
alone  ||| S:833 E:839 ||| RB
on  ||| S:839 E:842 ||| IN
the  ||| S:842 E:846 ||| DT
primary  ||| S:846 E:854 ||| JJ
outcome  ||| S:854 E:862 ||| NN
of  ||| S:862 E:865 ||| IN
overall  ||| S:865 E:873 ||| JJ
survival  ||| S:873 E:882 ||| NN
( ||| S:882 E:883 ||| -LRB-
10.1  ||| S:883 E:888 ||| CD
versus  ||| S:888 E:895 ||| CD
7.4  ||| S:895 E:899 ||| CD
months  ||| S:899 E:906 ||| NNS
respectively ||| S:906 E:918 ||| RB
)  ||| S:918 E:920 ||| -RRB-
and  ||| S:920 E:924 ||| CC
the  ||| S:924 E:928 ||| DT
secondary  ||| S:928 E:938 ||| JJ
outcomes  ||| S:938 E:947 ||| NNS
of  ||| S:947 E:950 ||| IN
progression-free  ||| S:950 E:967 ||| JJ
survival  ||| S:967 E:976 ||| NN
( ||| S:976 E:977 ||| -LRB-
PFS ||| S:977 E:980 ||| NNP
)  ||| S:980 E:982 ||| -RRB-
( ||| S:982 E:983 ||| -LRB-
5.6  ||| S:983 E:987 ||| CD
versus  ||| S:987 E:994 ||| CD
3.3  ||| S:994 E:998 ||| CD
months ||| S:998 E:1004 ||| NNS
) ||| S:1004 E:1005 ||| -RRB-
,  ||| S:1005 E:1007 ||| ,
best  ||| S:1007 E:1012 ||| RBS
overall  ||| S:1012 E:1020 ||| JJ
response  ||| S:1020 E:1029 ||| NN
to  ||| S:1029 E:1032 ||| TO
therapy  ||| S:1032 E:1040 ||| VB
( ||| S:1040 E:1041 ||| -LRB-
35.6 ||| S:1041 E:1045 ||| CD
%  ||| S:1045 E:1047 ||| NN
versus  ||| S:1047 E:1054 ||| IN
19.5 ||| S:1054 E:1058 ||| CD
% ||| S:1058 E:1059 ||| NN
) ||| S:1059 E:1060 ||| -RRB-
,  ||| S:1060 E:1062 ||| ,
disease  ||| S:1062 E:1070 ||| NN
control  ||| S:1070 E:1078 ||| NN
rate  ||| S:1078 E:1083 ||| NN
( ||| S:1083 E:1084 ||| -LRB-
81.1 ||| S:1084 E:1088 ||| NNP
%  ||| S:1088 E:1090 ||| NN
versus  ||| S:1090 E:1097 ||| IN
60 ||| S:1097 E:1099 ||| CD
% ||| S:1099 E:1100 ||| NN
)  ||| S:1100 E:1102 ||| -RRB-
and  ||| S:1102 E:1106 ||| CC
time-to-treatment  ||| S:1106 E:1124 ||| JJ
failure  ||| S:1124 E:1132 ||| NN
( ||| S:1132 E:1133 ||| -LRB-
4.8  ||| S:1133 E:1137 ||| CD
versus  ||| S:1137 E:1144 ||| CD
3.0  ||| S:1144 E:1148 ||| CD
months ||| S:1148 E:1154 ||| NNS
) ||| S:1154 E:1155 ||| -RRB-
,  ||| S:1155 E:1157 ||| ,
but  ||| S:1157 E:1161 ||| CC
not  ||| S:1161 E:1165 ||| RB
on  ||| S:1165 E:1168 ||| IN
duration  ||| S:1168 E:1177 ||| NN
of  ||| S:1177 E:1180 ||| IN
response  ||| S:1180 E:1189 ||| NN
( ||| S:1189 E:1190 ||| -LRB-
5.6  ||| S:1190 E:1194 ||| CD
months  ||| S:1194 E:1201 ||| NNS
versus  ||| S:1201 E:1208 ||| IN
4.7  ||| S:1208 E:1212 ||| CD
months ||| S:1212 E:1218 ||| NNS
) ||| S:1218 E:1219 ||| -RRB-
.  ||| S:1219 E:1221 ||| .
No  ||| S:1221 E:1224 ||| DT
safety  ||| S:1224 E:1231 ||| NN
issues  ||| S:1231 E:1238 ||| NNS
with  ||| S:1238 E:1243 ||| IN
cetuximab  ||| S:1243 E:1253 ||| NN
arose  ||| S:1253 E:1259 ||| VBD
beyond  ||| S:1259 E:1266 ||| IN
those  ||| S:1266 E:1272 ||| DT
already  ||| S:1272 E:1280 ||| RB
previously  ||| S:1280 E:1291 ||| RB
documented ||| S:1291 E:1301 ||| VBN
.  ||| S:1301 E:1303 ||| .
The  ||| S:1303 E:1307 ||| DT
manufacturer  ||| S:1307 E:1320 ||| NN
developed  ||| S:1320 E:1330 ||| VBD
a  ||| S:1330 E:1332 ||| DT
two-arm  ||| S:1332 E:1340 ||| JJ
state-transition  ||| S:1340 E:1357 ||| JJ
Markov  ||| S:1357 E:1364 ||| JJ
model  ||| S:1364 E:1370 ||| NN
to  ||| S:1370 E:1373 ||| TO
evaluate  ||| S:1373 E:1382 ||| VB
the  ||| S:1382 E:1386 ||| DT
cost-effectiveness  ||| S:1386 E:1405 ||| JJ
of  ||| S:1405 E:1408 ||| IN
cetuximab  ||| S:1408 E:1418 ||| FW
plus  ||| S:1418 E:1423 ||| FW
CTX  ||| S:1423 E:1427 ||| FW
versus  ||| S:1427 E:1434 ||| FW
CTX  ||| S:1434 E:1438 ||| NNP
alone ||| S:1438 E:1443 ||| RB
,  ||| S:1443 E:1445 ||| ,
using  ||| S:1445 E:1451 ||| VBG
clinical  ||| S:1451 E:1460 ||| JJ
data  ||| S:1460 E:1465 ||| NNS
from  ||| S:1465 E:1470 ||| IN
the  ||| S:1470 E:1474 ||| DT
EXTREME  ||| S:1474 E:1482 ||| NNP
trial ||| S:1482 E:1487 ||| NN
.  ||| S:1487 E:1489 ||| .
The  ||| S:1489 E:1493 ||| DT
ERG  ||| S:1493 E:1497 ||| NNP
recalculated  ||| S:1497 E:1510 ||| VBD
the  ||| S:1510 E:1514 ||| DT
base-case  ||| S:1514 E:1524 ||| JJ
cost-effectiveness  ||| S:1524 E:1543 ||| JJ
results  ||| S:1543 E:1551 ||| NNS
taking  ||| S:1551 E:1558 ||| VBG
changes  ||| S:1558 E:1566 ||| NNS
in  ||| S:1566 E:1569 ||| IN
parameters  ||| S:1569 E:1580 ||| NNS
and  ||| S:1580 E:1584 ||| CC
assumptions  ||| S:1584 E:1596 ||| NNS
into  ||| S:1596 E:1601 ||| IN
account ||| S:1601 E:1608 ||| NN
.  ||| S:1608 E:1610 ||| .
Subgroup  ||| S:1610 E:1619 ||| NNP
and  ||| S:1619 E:1623 ||| CC
threshold  ||| S:1623 E:1633 ||| NN
analyses  ||| S:1633 E:1642 ||| NNS
were  ||| S:1642 E:1647 ||| VBD
also  ||| S:1647 E:1652 ||| RB
explored ||| S:1652 E:1660 ||| VBN
.  ||| S:1660 E:1662 ||| .
The  ||| S:1662 E:1666 ||| DT
manufacturer  ||| S:1666 E:1679 ||| NN
reported  ||| S:1679 E:1688 ||| VBD
an  ||| S:1688 E:1691 ||| DT
incremental  ||| S:1691 E:1703 ||| JJ
cost-effectiveness  ||| S:1703 E:1722 ||| JJ
ratio  ||| S:1722 E:1728 ||| NN
( ||| S:1728 E:1729 ||| -LRB-
ICER ||| S:1729 E:1733 ||| NNP
)  ||| S:1733 E:1735 ||| -RRB-
of  ||| S:1735 E:1738 ||| IN
121,367  ||| S:1738 E:1746 ||| CD
pounds  ||| S:1746 E:1753 ||| NNS
per  ||| S:1753 E:1757 ||| IN
quality-adjusted  ||| S:1757 E:1774 ||| JJ
life-year  ||| S:1774 E:1784 ||| NN
( ||| S:1784 E:1785 ||| -LRB-
QALY ||| S:1785 E:1789 ||| NNP
)  ||| S:1789 E:1791 ||| -RRB-
gained  ||| S:1791 E:1798 ||| VBD
and  ||| S:1798 E:1802 ||| CC
an  ||| S:1802 E:1805 ||| DT
incremental  ||| S:1805 E:1817 ||| JJ
cost  ||| S:1817 E:1822 ||| NN
per  ||| S:1822 E:1826 ||| IN
life-year  ||| S:1826 E:1836 ||| NNP
gained  ||| S:1836 E:1843 ||| VBD
of  ||| S:1843 E:1846 ||| IN
92,226  ||| S:1846 E:1853 ||| CD
pounds ||| S:1853 E:1859 ||| NNS
.  ||| S:1859 E:1861 ||| .
Univariate  ||| S:1861 E:1872 ||| JJ
sensitivity  ||| S:1872 E:1884 ||| NN
analysis  ||| S:1884 E:1893 ||| NN
showed  ||| S:1893 E:1900 ||| VBD
that  ||| S:1900 E:1905 ||| IN
varying  ||| S:1905 E:1913 ||| VBG
the  ||| S:1913 E:1917 ||| DT
cost  ||| S:1917 E:1922 ||| NN
of  ||| S:1922 E:1925 ||| IN
day-case  ||| S:1925 E:1934 ||| JJ
infusion  ||| S:1934 E:1943 ||| NN
and  ||| S:1943 E:1947 ||| CC
the  ||| S:1947 E:1951 ||| DT
utility  ||| S:1951 E:1959 ||| NN
values  ||| S:1959 E:1966 ||| NNS
in  ||| S:1966 E:1969 ||| IN
the  ||| S:1969 E:1973 ||| DT
stable ||| S:1973 E:1979 ||| JJ
/ ||| S:1979 E:1980 ||| CD
response  ||| S:1980 E:1989 ||| NN
health  ||| S:1989 E:1996 ||| NN
state  ||| S:1996 E:2002 ||| NN
of  ||| S:2002 E:2005 ||| IN
the  ||| S:2005 E:2009 ||| DT
cetuximab  ||| S:2009 E:2019 ||| NN
plus  ||| S:2019 E:2024 ||| CC
CTX  ||| S:2024 E:2028 ||| NNP
arm  ||| S:2028 E:2032 ||| NN
had  ||| S:2032 E:2036 ||| VBD
the  ||| S:2036 E:2040 ||| DT
greatest  ||| S:2040 E:2049 ||| JJS
impact  ||| S:2049 E:2056 ||| NN
on  ||| S:2056 E:2059 ||| IN
the  ||| S:2059 E:2063 ||| DT
ICER ||| S:2063 E:2067 ||| NNP
.  ||| S:2067 E:2069 ||| .
Probabilistic  ||| S:2069 E:2083 ||| JJ
sensitivity  ||| S:2083 E:2095 ||| NN
analysis  ||| S:2095 E:2104 ||| NN
illustrated  ||| S:2104 E:2116 ||| VBD
that  ||| S:2116 E:2121 ||| DT
cetuximab  ||| S:2121 E:2131 ||| NN
plus  ||| S:2131 E:2136 ||| CC
CTX  ||| S:2136 E:2140 ||| NNP
is  ||| S:2140 E:2143 ||| VBZ
unlikely  ||| S:2143 E:2152 ||| JJ
to  ||| S:2152 E:2155 ||| TO
be  ||| S:2155 E:2158 ||| VB
cost-effective  ||| S:2158 E:2173 ||| JJ
for  ||| S:2173 E:2177 ||| IN
patients  ||| S:2177 E:2186 ||| NNS
with  ||| S:2186 E:2191 ||| IN
recurrent  ||| S:2191 E:2201 ||| NN
and ||| S:2201 E:2204 ||| CC
/ ||| S:2204 E:2205 ||| NNP
or  ||| S:2205 E:2208 ||| CC
metastatic  ||| S:2208 E:2219 ||| JJ
SCCHN ||| S:2219 E:2224 ||| NNP
,  ||| S:2224 E:2226 ||| ,
even  ||| S:2226 E:2231 ||| RB
at  ||| S:2231 E:2234 ||| IN
what  ||| S:2234 E:2239 ||| WP
would  ||| S:2239 E:2245 ||| MD
usually  ||| S:2245 E:2253 ||| RB
be  ||| S:2253 E:2256 ||| VB
considered  ||| S:2256 E:2267 ||| VBN
very  ||| S:2267 E:2272 ||| RB
high  ||| S:2272 E:2277 ||| JJ
levels  ||| S:2277 E:2284 ||| NNS
of  ||| S:2284 E:2287 ||| IN
willingness  ||| S:2287 E:2299 ||| NN
to  ||| S:2299 E:2302 ||| TO
pay  ||| S:2302 E:2306 ||| VB
for  ||| S:2306 E:2310 ||| IN
an  ||| S:2310 E:2313 ||| DT
additional  ||| S:2313 E:2324 ||| JJ
QALY ||| S:2324 E:2328 ||| NNP
.  ||| S:2328 E:2330 ||| .
With  ||| S:2330 E:2335 ||| IN
regard  ||| S:2335 E:2342 ||| NN
to  ||| S:2342 E:2345 ||| TO
the  ||| S:2345 E:2349 ||| DT
economic  ||| S:2349 E:2358 ||| JJ
model  ||| S:2358 E:2364 ||| NN
the  ||| S:2364 E:2368 ||| DT
appropriateness  ||| S:2368 E:2384 ||| NN
and  ||| S:2384 E:2388 ||| CC
reliability  ||| S:2388 E:2400 ||| NN
of  ||| S:2400 E:2403 ||| IN
parametric  ||| S:2403 E:2414 ||| JJ
survival  ||| S:2414 E:2423 ||| NN
projection  ||| S:2423 E:2434 ||| NN
beyond  ||| S:2434 E:2441 ||| IN
the  ||| S:2441 E:2445 ||| DT
duration  ||| S:2445 E:2454 ||| NN
of  ||| S:2454 E:2457 ||| IN
trial  ||| S:2457 E:2463 ||| NN
data  ||| S:2463 E:2468 ||| NNS
could  ||| S:2468 E:2474 ||| MD
not  ||| S:2474 E:2478 ||| RB
be  ||| S:2478 E:2481 ||| VB
fully  ||| S:2481 E:2487 ||| RB
explored  ||| S:2487 E:2496 ||| VBN
because  ||| S:2496 E:2504 ||| IN
of  ||| S:2504 E:2507 ||| IN
lack  ||| S:2507 E:2512 ||| NN
of  ||| S:2512 E:2515 ||| IN
information ||| S:2515 E:2526 ||| NN
.  ||| S:2526 E:2528 ||| .
The  ||| S:2528 E:2532 ||| DT
ERG  ||| S:2532 E:2536 ||| NNP
also  ||| S:2536 E:2541 ||| RB
questioned  ||| S:2541 E:2552 ||| VBD
the  ||| S:2552 E:2556 ||| DT
appropriateness  ||| S:2556 E:2572 ||| NN
of  ||| S:2572 E:2575 ||| IN
economic  ||| S:2575 E:2584 ||| JJ
modelling  ||| S:2584 E:2594 ||| NN
in  ||| S:2594 E:2597 ||| IN
this  ||| S:2597 E:2602 ||| DT
STA  ||| S:2602 E:2606 ||| NNP
as  ||| S:2606 E:2609 ||| IN
evidence  ||| S:2609 E:2618 ||| NN
is  ||| S:2618 E:2621 ||| VBZ
available  ||| S:2621 E:2631 ||| JJ
only  ||| S:2631 E:2636 ||| JJ
from  ||| S:2636 E:2641 ||| IN
a  ||| S:2641 E:2643 ||| DT
single  ||| S:2643 E:2650 ||| JJ
RCT ||| S:2650 E:2653 ||| NNP
.  ||| S:2653 E:2655 ||| .
In  ||| S:2655 E:2658 ||| IN
conclusion ||| S:2658 E:2668 ||| NN
,  ||| S:2668 E:2670 ||| ,
the  ||| S:2670 E:2674 ||| DT
ERG  ||| S:2674 E:2678 ||| NNP
considers  ||| S:2678 E:2688 ||| VBZ
that  ||| S:2688 E:2693 ||| IN
patients  ||| S:2693 E:2702 ||| NNS
with  ||| S:2702 E:2707 ||| IN
metastatic  ||| S:2707 E:2718 ||| JJ
SCCHN  ||| S:2718 E:2724 ||| NNP
were  ||| S:2724 E:2729 ||| VBD
not  ||| S:2729 E:2733 ||| RB
shown  ||| S:2733 E:2739 ||| VBN
to  ||| S:2739 E:2742 ||| TO
receive  ||| S:2742 E:2750 ||| VB
a  ||| S:2750 E:2752 ||| DT
significant  ||| S:2752 E:2764 ||| JJ
survival  ||| S:2764 E:2773 ||| NN
benefit  ||| S:2773 E:2781 ||| NN
from  ||| S:2781 E:2786 ||| IN
cetuximab  ||| S:2786 E:2796 ||| NN
plus  ||| S:2796 E:2801 ||| CC
CTX  ||| S:2801 E:2805 ||| NNP
compared  ||| S:2805 E:2814 ||| VBN
with  ||| S:2814 E:2819 ||| IN
CTX  ||| S:2819 E:2823 ||| NNP
alone  ||| S:2823 E:2829 ||| RB
and  ||| S:2829 E:2833 ||| CC
that  ||| S:2833 E:2838 ||| IN
even  ||| S:2838 E:2843 ||| RB
setting  ||| S:2843 E:2851 ||| VBG
a  ||| S:2851 E:2853 ||| DT
lower  ||| S:2853 E:2859 ||| JJR
price  ||| S:2859 E:2865 ||| NN
for  ||| S:2865 E:2869 ||| IN
cetuximab  ||| S:2869 E:2879 ||| NNS
would  ||| S:2879 E:2885 ||| MD
not  ||| S:2885 E:2889 ||| RB
strengthen  ||| S:2889 E:2900 ||| VB
the  ||| S:2900 E:2904 ||| DT
manufacturer ||| S:2904 E:2916 ||| NN
's  ||| S:2916 E:2919 ||| POS
case  ||| S:2919 E:2924 ||| NN
for  ||| S:2924 E:2928 ||| IN
cost-effectiveness ||| S:2928 E:2946 ||| JJ
.  ||| S:2946 E:2948 ||| .
